Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR mHealth and uHealth

Date Submitted: Jun 22, 2020
Date Accepted: Apr 11, 2021

The final, peer-reviewed published version of this preprint can be found here:

Comparative Analysis of Single and Combined Antipyretics Using Patient-Generated Health Data: Retrospective Observational Study

Park YR, Kim H, Park JA, Ahn SH, Chang S, Shin JW, Kim M, Lee JH

Comparative Analysis of Single and Combined Antipyretics Using Patient-Generated Health Data: Retrospective Observational Study

JMIR Mhealth Uhealth 2021;9(5):e21668

DOI: 10.2196/21668

PMID: 34037528

PMCID: 8190646

Comparative analysis of single and combined antipyretics using patient-generated health data: A retrospective observational study

  • Yu Rang Park; 
  • Hyery Kim; 
  • Ji Ae Park; 
  • Sang Hyun Ahn; 
  • Seyun Chang; 
  • Jae Won Shin; 
  • Myungchan Kim; 
  • Jae-Ho Lee

ABSTRACT

Background:

Although fever is one of the most common symptoms in children and is the physiological response of the human immune system to external pathogens, the effectiveness studies of single and combined antipyretic therapy are relatively less due to lack of data. In this study we used large-scale patient-generated health data (PGHD) from mobile applications to compare antipyretic affects between single and combination antipyretics.

Objective:

We aimed to compare antipyretic affects between single and combination antipyretics using large-scale patient-generated health data from mobile applications.

Methods:

This study was conducted using records for feverish children from July 2015 to June 2017 using the Fever Coach mobile application. Totally, 3,584,748 temperature records and 1,076,002 antipyretic records in 104,337 children were analyzed. Antipyretic efficacy was measured by the mean difference in the area under the temperature change curve (AUC) from baseline for 6, 8, 10, and 12 hours after antipyretics between single and combination groups.

Results:

The single antipyretic group comprised 152,017 cases, and the combination group comprised 54,842 cases. Acetaminophen was the most used single agent (40.1%), and acetaminophen plus dexibuprofen was the most common combination (51.3%). There were inappropriate usages, including triple combination (0.6%) and use under 38℃ (5.5%). Combination antipyretic use increased with temperature; 23.8% of cases used a combination treatment when 38℃ ≤ temperature < 39℃, while 41.4% used a combination treatment when 40℃ ≤ temperature. The absolute value of AUC at each hour was significantly higher in the single than in the combination group; this trend was consistently observed, regardless of the type of antipyretics. In particular, the delta fever during the first 6 hours between the two groups showed the highest difference. The triple combination showed the lowest delta fever among all cases.

Conclusions:

Combination antipyretics did not have favorable effects, regardless of the combination. Single antipyretics would be effective to reduce fever and relieve discomfort in febrile children.


 Citation

Please cite as:

Park YR, Kim H, Park JA, Ahn SH, Chang S, Shin JW, Kim M, Lee JH

Comparative Analysis of Single and Combined Antipyretics Using Patient-Generated Health Data: Retrospective Observational Study

JMIR Mhealth Uhealth 2021;9(5):e21668

DOI: 10.2196/21668

PMID: 34037528

PMCID: 8190646

The author of this paper has made a PDF available, but requires the user to login, or create an account.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.